Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel.

Assessment of safety after repeated skin application.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer; LEO Pharma
• Collaborator: Bayer
• Treatments: Azelaic acid

Criteria

Inclusion Criteria:

• diagnosis of moderate papulopustular rosacea

• free of any clinically significant disease

Exclusion Criteria:

• body weight less than 50 or more than 130 kg

• clinically significant disease which could interfere with the study